<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900828-0071</DOCNO><DOCID>900828-0071.</DOCID><HL>   Whittaker Considers   Spinoff to Shareholders   Of Biotechnology Unit</HL><DATE>08/28/90</DATE><SO>WALL STREET JOURNAL (J), PAGE C16</SO><CO>   WKR</CO><IN>EARNINGS (ERN)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><LP>   LOS ANGELES -- Whittaker Corp. said it may spin off toshareholders its biotechnology unit, which will contributeabout 17% of Whittaker's expected $190 million sales for thecurrent fiscal year.   A Whittaker spokesman said a decision hadn't yet beenreached but said &quot;chances are we'll do it,&quot; probably earlynext year. The company's directors and secured lenders wouldhave to approve the transaction, however. It would also haveto be structured on a tax-free basis, Whittaker said.</LP><TEXT>   The unit makes and sells diagnostic tests used by doctorsand hospitals and laboratory cell-culture media.   Whittaker also posted results for its third quarter, endedJuly 31. In the period, the concern had net income of $4million, or 47 cents a share, compared with $5 million, or 62cents a share. Year-earlier net included a loss fromcontinuing operations of $3.2 million and a gain of $5.5million on the disposal of discontinued operations. Salesrose 7.1% to $48 million from $44.8 million.   Whittaker has sold several businesses in the past year aspart of a recapitalization plan. Whittaker's continuingoperations, besides the biotechnology unit, are in aerospace.   For its first nine months, an $85.2 million gain on thedisposal of discontinued operations more than offset a$363,000 loss from continuing operations. Net was $80.7million, or $9.61 a share, compared with $22.4 million, or$3.03 a share.   Marcus Schloss andamp; Co., a New York investment firm, alsodisclosed in a filing with the Securities and ExchangeCommission that it boosted its stake in Whittaker to 7.6% forinvestment purposes.</TEXT></DOC>